On Friday, Gilead Sciences, Inc. (GILD) stock saw a decline, ending the day at $88.4 which represents a decrease of $-3.71 or -4.03% from the prior close of $92.11. The stock opened at $91.71 and ...

An update from the PURPOSE 2 trial focused on adherence and pharmacokinetics data for lenacapavir, used to prevent HIV.

RBC Capital analyst Brian Abrahams raised the firm’s price target on Gilead (GILD) to $84 from $81 but keeps a Sector Perform rating on the ...

RBC Capital analyst Brian Abrahams maintained a Hold rating on Gilead Sciences (GILD – Research Report) today and set a price target of $84.00.

The scope of Gilead Sciences' recent round of layoffs is coming into clearer view with the revelation that the company is ...

This report explores the benefits and challenges of NHS-industry partnerships aiming to catalyse improvements in the health ...

Echo IQ executive chair Andrew Grover is generally cheerful and optimistic, but wasn't in the weeks leading up to the US regulator’s approval of its artificial intelligence-based aortic stenosis (AS) ...

Citigroup upgraded shares of Gilead Sciences (NASDAQ:GILD – Free Report) to a strong-buy rating in a research report sent to ...

Fintel reports that on November 15, 2024, Wolfe Research initiated coverage of Gilead Sciences (NasdaqGS:GILD) with a ...

On Friday, Gilead Sciences, Inc. (NASDAQ:GILD) revealed data from a two-and-a-half-year interim analysis from the ongoing ...

Gilead Sciences, a Bay Area-headquartered biotech and pharmaceutical company, is laying off 104 workers in Foster City, with ...